Commentary from expert clinician highlights that GH001’s performance across patients with extensive treatment histories could benefit those nonresponsive to multiple prior antidepressants.

Analysts remain optimistic about GH Research’s potential, signaling continued coverage and possible re‑rating based on trial outcomes and upcoming Phase 3 development.

Despite positive clinical data, the stock fell about 11% over the past week, indicating mixed near‑term market sentiment.

Correlation analyses found no meaningful link between number of prior treatment failures and MADRS improvement at Day 8 or at Month 6 (r values around −0.13 to −0.10; P>0.4).

GH Research reports peer‑reviewed Phase 2b results for GH001 (inhaled mebufotenin) in treatment‑resistant depression, with primary results published in JAMA Psychiatry and a post hoc analysis in Psychopharmacology Bulletin showing efficacy largely independent of prior antidepressant treatment failures.

The press release carries forward‑looking statements and notes ongoing and planned Phase 3 pivotal programs for GH001.

The JAMA Psychiatry trial reported a primary endpoint win, with a 15.5‑point greater reduction in MADRS from baseline for GH001 versus placebo by Day 8 (P<0.0001).

GH Research’s 2025 year‑end financials show Q4 EPS of −$0.22, with progress toward Phase 3 trials after the Phase 2b success, contributing to revised analyst outlooks.

GH001 is a mebufotenin formulation delivered by inhalation, being developed to treat TRD, with a pathway toward global Phase 3 trials.

Context contrasts GH001’s apparent independence from prior treatment failures with STAR*D findings of diminishing remission with successive trials, underscoring the potential novelty of GH001.

Limitations include post hoc design, small subgroup sizes (7–13 per subgroup), European and white‑only sample, and an open‑label extension without placebo control; authors call for larger replication.

Safety profile showed adverse events in 72.5% of GH001‑treated participants, mostly mild to moderate, with no serious AEs or discontinuations due to AEs.